Is loss of function of PCSK9 a key in the protection against atherosclerotic cardiovascular disease?

被引：0
|
作者：
Reuwer, AQ [1 ]
机构：
[1] Univ Utrecht, Fac Med, NL-3508 TC Utrecht, Netherlands
来源：
CLINICAL GENETICS | 2006年 / 70卷 / 01期
关键词：
D O I：
10.1111/j.1399-0004.2006.0627b.x
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：15 / 17
页数：3
相关论文
共 50 条
  • [21] PCSK9 inhibitors in the management of atherosclerotic cardiovascular disease: Current clinical trials and future directions
    Nie, Wenyi
    Yue, Yingbin
    Hu, Jingqing
    ATHEROSCLEROSIS, 2024, 399
  • [22] PRODUCTION AND PURIFICATION OF RECOMBINANT PCSK9 TO STUDY PCSK9 GAIN OF FUNCTION (GOF) AND LOSS OF FUNCTION (LOF) MUTANTS
    Chemello, K.
    Benito Vicente, A.
    Larrea Setubal, A.
    Martin, C.
    Lambert, G.
    ATHEROSCLEROSIS, 2018, 275 : E165 - E165
  • [23] Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease
    Dayoub, Elias J.
    Eberly, Lauren A.
    Nathan, Ashwin S.
    Khatana, Sameed Ahmed M.
    Adusumalli, Srinath
    Navar, Ann Marie
    Giri, Jay
    Groeneveld, Peter W.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (09):
  • [24] PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
    Tavori, Hagai
    Giunzioni, Ilaria
    Fazio, Sergio
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2015, 22 (02) : 126 - 132
  • [25] EVALUATING THE IMPACT OF PCSK9 INHIBITORS ON CARDIOVASCULAR DISEASE
    Karcher, H.
    Wiecek, W.
    Casciano, R.
    Coeytaux, E.
    Bixer, S.
    Amzal, B.
    Abenhaim, L.
    VALUE IN HEALTH, 2017, 20 (09) : A630 - A630
  • [26] Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    Cohen, JC
    Boerwinkle, E
    Mosley, TH
    Hobbs, HH
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12): : 1264 - 1272
  • [27] Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    不详
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2006, 13 (03): : 471 - 471
  • [28] Lipidomic profile in patients with a very high risk of atherosclerotic cardiovascular disease on PCSK9 inhibitor therapy
    Huang, Kui
    Wen, Xiao-Qin
    Ren, Ning
    Yang, Li
    Gao, Bo
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2021, 22 (02) : 461 - 467
  • [29] Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease
    Smith, Alex
    Johnson, Drew
    Banks, Joshua
    Keith, Scott W.
    Karalis, Dean G.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (17)
  • [30] PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease
    Page, Michael M.
    Watts, Gerald F.
    DIABETES OBESITY & METABOLISM, 2018, 20 (02): : 270 - 282
12345